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The main difficulty in the development of ATP antag-
onist kinase inhibitors is target specificity, since the
ATP-binding motif is present in many proteins. We
introduce a strategy that has allowed us to identify
compounds from a kinase inhibitor library that block
the cyclin-dependent kinases responsible for regu-
lating transcription, i.e., CDK7 and especially CDK9.
The screening cascade employs cellular phenotypic
assaysbasedonmitotic indexandnuclearp53protein
accumulation. This permitted us to classify com-
pounds into transcriptional, cell cycle, and mitotic
inhibitor groups. We describe the characterization of
the transcriptional inhibitor class in terms of kinase
inhibition profile, cellular mode of action, and selec-
tivity for transformed cells. A structural selectivity
rationale was used to optimize potency and biophar-
maceutical properties and led to the development of
a transcriptional inhibitor, 3,4-dimethyl-5-[2-(4-piper-
azin-1-yl-phenylamino)-pyrimidin-4-yl]-3H-thiazol-2-
one, with anticancer activity in animal models.
INTRODUCTION
Cyclin-dependent kinases (CDKs) are key cell cycle regulators
and some also have regulatory functions in mRNA transcription
at the level of RNA polymerase-II (RNAP-II) (Hirose and Ohkuma,
2007). CDKs 1, 2, 7, 8, 9, and 11 have all been implicated in the
phosphorylation of the C-terminal domain (CTD) of the largest
RNAP-II subunit (Pinhero et al., 2004), but the most important
ones are CDK7-cyclin H and CDK9-cyclin T (Ramanathan
et al., 2001). The CTD contains repeating Tyr-Ser-Pro-Thr-Ser-
Pro-Ser heptad sequences and the phosphorylation status of
the Ser residues at positions 2 and 5 has been shown to be
important in the activation of RNAP-II.
CDK7-cyclin H associates with the RING-finger protein MAT1
in the general transcription factor IIH (TFIIH) and also acts as anChemistry & Biology 17, 1111–1activating kinase for other CDKs. Unlike other CDKs, CDK9
appears to function exclusively in transcriptional regulation.
It forms complexes with cyclin T1, T2, or K, which participate
in the positive transcription elongation factor b (P-TEFb) (Michels
et al., 2003). CDK9 phosphorylates both Ser-2 and Ser-5 of the
CTD heptad (Pinhero et al., 2004), playing a predominant role
during transcriptional elongation, in contrast to CDK7, which
primarily phosphorylates Ser-5 of RNAP-II at the promoter as
part of transcriptional initiation (Gomes et al., 2006).
Overexpression of cyclins or suppression of CDK-inhibitory
proteins (CDKIs) is frequently observed in cancers and ectopic
expression of CDKIs in tumor cells restores cell cycle control,
leading to cell cycle arrest or apoptosis (Shapiro and Harper,
1999). However, it is now clear that many CDKs and cyclins
associated with the cell cycle are functionally redundant, which
suggests that targeting individual cell cycle CDKs may not be
an optimal therapeutic strategy (Barriere et al., 2007). The
anticancer activity in preclinical models of the experimental
CDK inhibitor drugs flavopiridol (alvocidib; Aventis/NCI) and
R-roscovitine (seliciclib, CYC202; Cyclacel) are believed to result
mostly from the transcriptional inhibition mechanism (Fischer
and Gianella-Borradori, 2005). Flavopiridol targets a number of
CDKs and other kinases, and transcription inhibition caused by
this compound in cancer cells was originally thought to be
mediated by inhibition of CDK7 (Harper and Elledge, 1998).
Recent data, however, suggest that CDK9 inhibition plays
a more important role (Chen et al., 2005). Treatment of cancer
cells with flavopiridol results in inhibition of RNAP-II CTD phos-
phorylation, thus blocking transcription and inducing apoptosis
by reducing mRNA levels of antiapoptotic proteins (Gojo et al.,
2002). Selective induction of apoptosis in transformed cells by
downregulation of antiapoptotic proteins through transcriptional
CDK inhibition has also been demonstrated for R-roscovitine
(MacCallum et al., 2005).
Clinical trials results show flavopiridol monotherapy efficacy
in hematological cancers, especially chronic lymphocytic
leukemia, which is particularly sensitive to transcriptional inhibi-
tion (Byrd et al., 2007). Many clinical and preclinical pan-CDK
inhibitor compounds are potent CDK9 inhibitors and their anti-
proliferative properties emanate from transcriptional inhibition
to a large extent (Joshi et al., 2007; Karaman et al., 2008;121, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1111
Figure 1. Identification of CDK Transcrip-
tional Inhibitors by Cell-Based Assays in
A2780 Cancer Cells
Cells were treated with test compounds or assay
diluent only (control) at 0.63 mM (A, B) or the
concentrations indicated (C) for 7 hr (A–C) or
24 hr (D). MI was measured by determining the
percentages of phospho-histone-H3 positive cells
(A). Nuclear accumulation of p53 was assessed by
immunofluorescent staining (B). Transcription
inhibitors induce a time-dependent increase in
p53 protein (C) and an apoptotic signal through
activation of caspases-3/7 (D). See also Figures
S1. Data are represented as mean ± SD.
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Transcriptional CDK InhibitorsWang and Fischer, 2008; Zhang et al., 2008). However, truly
CDK7- and CDK9-selective compounds have not been reported
to date (Wang and Fischer, 2008).
Here, we report the results that have led to the identification of
potent and selective new pharmacological CDK transcriptional
inhibitors from our 2-anilino-4-(heteroaryl)-pyrimidine kinase
inhibitor compound library (Wang et al., 2004a, 2004b;
Wu et al., 2003). We have developed a cell-based screening
cascade that has enabled us effectively to delineate a pharmaco-
phore subseries of compounds characterized by selective
antiproliferative effects in tumor cells through transcriptional
CDK inhibition. This cascade has permitted us to distinguish
phenotypically and biochemically compounds that inhibit
RNAP-II CDKs from those that act predominantly through inhibi-
tion of the cell cycle CDKs (1, 2, 4), or the closely related mitotic
aurora kinases. We use assays for mitotic index (MI), and p53
protein level measurements as a proxy measure for general tran-
scriptional inhibition, for initial mechanistic compound classifica-
tion, followed by more specific cell biological screens, such as
caspase-3/7 activation assays, for more detailed compound
mode-of-action analysis and classification (Griffiths et al.,
2004, 2008; Wang et al., 2004a, 2005).
RESULTS
Cellular Phenotypic Classification
The effects of treatment of A2780 (ovarian), NCI-H460 (non-small
cell lung), and A549 (lung) tumor cell lines with compounds from
our kinase inhibitor library were assessed using high-throughput
cell biological assays based on an automated microscopy
system. Among these, MI and p53 protein level assays were
found to be the most informative for classification of the library
subgroups that target the cell cycle or transcription, respectively.
Based on time-course experiments, a 7 hr treatment period with
test compounds was chosen to identify maximum effects on cell
cycle or induction of p53 protein levels. p53 expression is
regulated at the level of protein stability, and the increase in1112 Chemistry & Biology 17, 1111–1121, October 29, 2010 ª2010 Elsevier Ltd All rights resp53 protein levels after treatment with
transcriptional inhibitors, including flavo-
piridol, is attributed to the downregulation
of Mdm2 (Demidenko and Blagosklonny,
2004; Lu et al., 2001; Radhakrishnan and
Gartel, 2006), which is a well-established
negative regulator of p53 protein (Michaeland Oren, 2003). Compounds were typically screened using
a concentration range of 0.04–20 mM, which permitted assess-
ment of both potency and phenotypic specificity. Examination
of MI and p53 protein levels resulted in identification of three
classes of compounds: class-1 compounds decreased MI and
induced high levels of nuclear p53 protein; class-2 compounds
increased MI, but had minimal effects on p53 protein levels;
and class-3 compounds decreased MI and had minimal effects
on p53 levels. Representatives of each class of compounds
were further evaluated by enzymatic screening and cellular
mode-of-action investigations.
MI was used as an indicator of cell cycle status in unsynchro-
nized proliferating cells. Figure 1A illustrates the response of
A2780 cells and is representative across the concentration range
(the results from a primary MI and p53 screen of a set of 220
compounds is shown in Figure S1A, available online). Class-2
compounds, exemplified by a compound we have designated
MKI-1 (for mitotic kinase inhibitor), delayed cells in mitosis and
increased the overall MI of the cell population. Many of these
compounds were subsequently identified as selective inhibitors
of aurora kinases (data not shown; Wang et al., 2010). Class-1
compounds such as 1, 3, 4, 6, 7, and 14 (Table 1) decreased
MI, indicating a reduction in the number of cycling cells (Fig-
ure 1A) and increased the number of cells with high levels of
nuclear accumulation of p53, typically with a 3- to 6-fold increase
in A2780 (Figure 1B). To determine if p53 induction was a result
of a DNA damage response (Kastan et al., 1991), additional
experiments were carried out using an independent DNA-
damage response marker, phosphorylated histone H2AX
(Rogakou et al., 1998). Treatment of MCF-7 cells with either
doxorubicin, a classical DNA-damaging agent (Gewirtz, 1999),
or 1 resulted in accumulation of p53 (Figure 1c). Treatment
with 1 had no effect on the level of histone H2AX phosphoryla-
tion, which was increased substantially by doxorubicin
(Figure S1B). A likely mechanism of p53 accumulation for
class-1 compounds is reduction in the transcription and expres-
sion of Mdm2, the ubiquitin ligase responsible for degradation oferved
Table 1. Structures and Biological Activity of Selected CDK Inhibitors
Structure
No. Formula R1 R2 R3




















2 I NHEt SO2NH2 H
3 I NHMe SO2NH2 H
4 I NHMe SO2NHMe H
5 I NH2 SO2NHMe H
6 I NHMe SO2Me H
7 I NHEt SO2Me H
8 I NH2 SO2NHEt H
9 I NHMe SO2-morpholine Me
10 I NH2 SO2-morpholine Me
11 II Me H SO2NH(CH2)2OMe
12 II Me CN H
13 II Me NO2 Me
14 II Me H Piperazine
No. Kinase inhibition, Ki (nM) 72 hr MTT, IC50 (nM)
CDK1 CDK2 CDK4 CDK7 CDK9 A2780 MES-SA
1 73±31 <1 19±17 73±5 4.6±5.2 41±2 140±13
2 691±81 403±29 132±53 56±24 4.5±1.4 666±106 1608±235
3 67±11 2.4±1.3 9.1±2.9 25±7 0.80±0.79 12±5 76±10
4 334±3 33±1 20±7 107±71 4.3±2.1 178±44 278±75
5 233±32 26±3 163±73 127±48 4.3±1.8 205±156 428±45
6 86±63 1.6±0.2 94±4 91±13 0.29±0.27 87±2 93±15
7 >500 7.6±1.5 139±23 47±24 0.96±0.14 101±2 50±15
8 660±353 47±16 391±50 193±13 5.9±1.5 332±13 425±65
9 >500 >500 >500 3,469±1,526 6.7±3.0 760±336 370±43
10 >500 >500 >500 304±87 8.5±1.3 692±35 169±45
11 4.1±0.8 0.11±0.05 >500 940±55 14±2 221±75 98±10
12 399±16 0.52±0.11 102±53 6.8±3.0 1.9±2.3 216±20 367±30
13 3.0±0.5 28±3 60±18 0.56±0.13 5.9±3.3 34±1 126±30
14 449±48 149±40 68±28 2.3±0.2 0.38±0.27 131±9 150±16
See also Table S1. Data are represented as mean ± SD.
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Transcriptional CDK Inhibitorsp53 (Lu et al., 2001). Direct evidence for this mechanism was
obtained after detailed investigations with compound 14 (see
below). Nuclear p53 protein levels were subsequently used as
an indicator of general transcriptional inhibition and this corre-
lated well with biochemical selectivity for CDK 7 and 9 inhibition
(Figure 2).
The third class of inhibitors, exemplified by the compounds
designated CCI-1 and CCI-2 (for cell-cycle inhibitors) in Figures
1A and 1B, reduced MI but had no significant effect on p53
protein levels. These compounds were subsequently identified
as selective cell cycle inhibitors, which cause stage-specific
cell cycle arrest and prevent mitotic entry (Wang et al., 2005).
CDK Transcriptional Inhibitors Induce Apoptosis
in Tumor Cells
Caspases 3 and 7 are the most crucial effector components of
cell death pathways that culminate in the cleavage of a number
of important cellular proteins (Fuentes-Prior andSalvesen, 2004).Chemistry & Biology 17, 1111–1We found that all of the compounds that we had identified as
transcriptional CDK inhibitors (class-1) were capable of inducing
a caspase-3/7 response in tumor cell lines, including A2780,
NCI-H460, MES-SA (uterine sarcoma), and HT-29 (colon adeno-
carcinoma). When, e.g., A2780 cells were treated with 1, 3, 4, 6,
7, and 14 for 24 hr, substantial induction of apoptosis was
observed, typically a >7-fold induction of caspase-3/7 activa-
tion, compared with class-2 (MKI-1 and 2) and class-3 com-
pounds (CCI-1 and 2), or controls (Figure 1D). Caspase activa-
tion was only observed in transformed lines and not in the
nontransformed fetal lung cell line WI-38, despite it being able
to activate caspases 3/7 in response to other classes of com-
pounds. In all cases, full induction of caspase activity occurred
over a narrow concentration range as an all-or-nothing response
(Figure 3A). Selective induction of apoptosis in transformed lines
was confirmed by TUNEL of A2780 and WI-38 cells treated
with compound 14. Cell-cycle arrest was not detected, and
TUNEL-positive cells originated from all stages of the cell cycle121, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1113
Figure 2. Cellular CDK Selectivity
For each test compound the antiproliferative 72 hr
MTT assay IC50 value against A2780 cells was
divided by the Ki values against individual CDKs
(determined in biochemical kinase assays) and
the ratios were plotted. A low ratio (ratios of %1
are shown as unity for the sake of clarity) indicates
that antiproliferative activity is unlikely to be due to
inhibition of the CDK in question. It is apparent that
CDK9 inhibition is important for all transcriptional
inhibitors (1–10 and 14). No other kinase tested
shows such a correlation. Of the nontranscrip-
tional inhibitors, 11, 12, and CCI-2 show poten-
tially significant cellular inhibition of CDK9 but
these compounds also show strong activity
against other kinases. See also Figures S2.
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Transcriptional CDK Inhibitors(Figure 3B). This was observed in all tumor cell lines testedwhere
an intact caspase-3/7 pathway was present, irrespective of
mutant or wild-type p53 status. Class-1 compounds thus lead
to apoptotic tumor cell death, and not to a stage-specific cell
cycle block.
CDK Transcriptional Inhibitor Analogs: Design and Lead
Optimization
The 2-anilinopyrimidine compounds in Table 1 were prepared
using procedures as described (Wang et al., 2004a). Previously
established SARs of a series of 2-anilino-4-(thiazol-5-yl)pyrimi-
dines with respect to CDK2 suggested the importance of substit-
uents at C2 of the thiazole ring (Wang et al., 2004a). Introduction
of amino functions in the context of either meta- or para-
substituted anilines at the pyrimidine C2 resulted in increased
inhibition not only of CDK2, but also CDK9. CDK2-bound crystal
structures of such compounds, e.g., 1, reveal that the thiazole
C2-amino group interacts strongly with the Asp145 and Lys33
side chains and enhances the hydrophobic interaction of the
thiazol-4-yl methyl group with the Phe gatekeeper residue
present in all CDKs (Phe80 in CDK2) (Wang et al., 2004a). In addi-
tion, a number of H-bonding interactions between the thiazole
C2-alkylamino groups andGln131 and Asp86 were also observed.
Substitution of the thiazole C2 with bulkier groups, such as
phenyl, pyridyl, or other heterocycles, resulted in significantly
reduced activity. The thiazol-4-yl methyl group was also found
to be intolerant of modification. Certain meta- or para-substitu-
tions of the aniline ring were well tolerated and manipulation of
these substituents led to a number of inhibitors possessing
varying CDK selectivity profiles. Similar substituents in the ortho
position abolished CDK-inhibitory activity in all cases.
Application of our screening cascade revealed that
compoundswith the transcriptional inhibitor phenotype predom-
inantly inhibit CDK7 and CDK9 and show varying selectivity
toward other CDKs, in particular CDK2 and CDK4, in enzymatic1114 Chemistry & Biology 17, 1111–1121, October 29, 2010 ª2010 Elsevier Ltd All rights resassays (Figure 2). A derivative with a
sulfonamide substituent at the aniline
meta position and containing a methyla-
mino group at the thiazole C2 position
(3) was found to be one of themost potent
transcriptional inhibitors in the class
(Table 1). This compound also showedconsiderable potency against CDK2-cyclin E and CDK4-cyclin
D1. Furthermore, it exhibited potent in vitro antitumor activity in
a number of cancer cell lines. Replacement of the methylamino
with an ethylamino group at thiazole C2 afforded another
comparatively selective inhibitor of CDK7 and CDK9 (2),
althoughwith reducedpotency. This also resulted in a substantial
reduction in antiproliferative activity against tumor cell lines.
Methylation of the sulfonamide at the meta position of the
aniline ring (4) also reduced CDKs 9, 2, and 4 activity somewhat
compared to compound 3. Again this was accompanied by
an antiproliferative potency reduction. Analog 5, which has a
primary amino group at the thiazole C2 showed potency and
selectivity profiles comparable to 4. Similar antiproliferative
activity was observed for both compounds. Replacement of
the sulfonamide of 3 with a methylsulfonyl function afforded
another picomolar CDK9 inhibitor (6) that retained similar
potency and selectivity with respect to CDKs 1, 2, and com-
pared to 3. The structural modification resulted in 10-fold lower
activity against CDK4, however. As expected, 6 also displayed
potent cytotoxicity in cells. Keeping the aniline portion of 6
constant, but replacing the thiazole C2 substituent with the
larger ethylamino group led to 7, with 5-fold reduced inhibition
of CDK2 and 3-fold reduced inhibition of CDK9 compared
with 6. An ethyl group on the sulfonamide function (8), rather
than the methylsulfonamide in 5, in the context of the thiazole
C2 primary amine, resulted in slightly reduced potency
throughout.
In order to assess if targeting CDK9 alone would be sufficient
for a compound to exhibit the transcriptional inhibitor pheno-
type, a number of selective CDK9 inhibitors were designed.
During lead optimization, we observed that introduction of bulky
substituents at the meta position of the aniline resulted in unfa-
vorable contacts with CDK1 and CDK2, whereas simple nonio-
nizable alkyl functions at the para position were poorly tolerated
in terms of CDK4 activity. Combination of such substitutionerved
Figure 3. Selective Induction of Apoptosis
in Transformed Cells
(A) Caspase-3/7 activation assays show 14 selec-
tively to induce caspase activation in the
transformed A2780 cell line but not in the non-
transformed WI-38 line. Treatment with CCI-3
demonstrates caspase induction in both cell lines.
(B) Flow cytometric analysis was performed and
cell death (by TUNEL assay gating; ordinate) was
correlated with cell cycle stage (by DNA content
gating; abscissa). Cells were treated with assay
diluent only (control) or with 2 mM compound 14
(treated) for 24 hr. Treatment with 14 (2 mM)
resulted in 31% TUNEL-positive A2780 cells cor-
responding to all cell cycle phases, whereas
similar treatment of WI-38 cells gave rise to only
4.8% TUNEL-positive cells. See also Table S2.
Data are represented as mean ± SD.
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(morpholine-4-sulfonyl)aniline derivatives 9 and 10. Both com-
pounds were potent CDK9 inhibitors essentially devoid of
activity against CDKs 1, 2, and 4, while retaining modest
potency against CDK7. Application of 9 and 10 in the screening
cascade revealed that both compounds clearly belonged to
class-1. However, these compounds exhibited reduced cellular
potency in comparison to other low nanomolar Ki CDK9 inhibi-
tors, which, in contrast, were potent against one or more
additional CDKs.
Structural modification by transposition of various sulfon-
amide or alkylsulfone functions from the meta to the para posi-
tion of the aniline ring generally resulted in somewhat reduced
potency against all CDKs except CDK2. Thus, compound 11,
although active against CDK9, inhibits CDK2 with almost
100-fold higher potency. However, having achieved optimal
CDK9 selectivity over CDK2 and CDK4 with compounds such
as 9 and 10, we turned our attention to CDK7 inhibition. We
discovered that a number of compounds with a 3H-thiazol-2-
one (formula II in Table 1) rather than a thiazole (formula I) system
at the pyrimidineC4 displayed enhanced potency against CDK7.
This was especially true for analogs with amethylated thiazolone
N3 and small electron-withdrawing aniline meta substituents,
such as 12. Addition of amethyl group at the aniline para position
again improved selectivity and also afforded our most potent
CDK7 inhibitor compound 13.
As noted above, bulky aniline para substituents were not
conducive to CDK9 selectivity. If, however, substituents con-
taining an amino group that is charged at physiological pHChemistry & Biology 17, 1111–1121, October 29, 2010 ªwere introduced at the para position in
the context of the pyrimidinyl C4 thiazo-
lone system, both CDK7 and CDK9
potency was preserved, while maintain-
ing selectivity with respect to the other
CDKs to some extent. The representative
compound in this regard is 14, which
potently inhibits not only CDK7, but
also CDK 9. CDKs 1, 2, 4, on the other
hand, are inhibited at least 30-fold less
potently.Compound 14was also assessed for its selectivity in a panel of
closely related non-CDK kinases. The results in Table S1A show
that a range of kinases are inhibited by 14 at the mid-nanomolar
to low micromolar IC50 level. Considering the fact that 14 is
a mid-picomolar IC50 CDK9 inhibitor and comparing with the
non-CDK kinase inhibited most potently (VEGFR2 IC50 =
180 nM), this gives a selectivity of at least 400-fold. This
compound was also passed through a more extensive protein
kinase panel that contains kinases representing most signaling
pathways. The results again show that certain non-CDK kinases
are inhibited by 14, but at concentrations several orders of
magnitude higher than those relevant to CDK7 and CDK9 inhibi-
tion (Figure S1C).
Compound 14 was further assessed for its biopharmaceutical
properties (Table S1B): it has low lipophilicity (logP = 1.1) and
good aqueous solubility. Membrane permeability was moderate
with a Papp value of 2.43 10
6 cm/s byCaco-2monolayer assay.
Furthermore, 14 exhibited good in vitro metabolic stability with
a half-life of 50 min and low intrinsic clearance in a liver micro-
some assay. Plasma protein bindingwas also low (36%unbound
fraction). In order to confirm this, 14 was subjected to rat
pharmacokinetic (PK) analysis following a single intravenous
(i.v.) dose of 5 mg/kg or an oral (p.o.) dose of 50 mg/kg. Mean
plasma concentrations were used to calculate the PK parame-
ters (Table S1B). The compound was found to be orally bioavail-
able (F = 70%) with a plasma half-life of 5 hr following p.o.
administration, and a large volume of distribution. The exposure
values obtained show that multiples of in vitro bioactive concen-
trations can easily be achieved at good dose potency.2010 Elsevier Ltd All rights reserved 1115
Figure 4. Structural Basis for Compound CDK Selectivity
Electron density (gray mesh) and two plausible binding conformations (green and cyan CPK sticks) each for 14 (A) and 11 (B) (contoured at 1.2 and 1.0 s, respec-
tively) in the complex crystal structures with CDK2 (gray CPK surface). Observed interactions of 11 (C) and 14 (D) with the ATP-binding site of CDK2 (gray),
corresponding residues from an aligned structure of a catalytically competent CDK2-cyclin A-ATP/Mg structure are shown (PDB #1QMZ; salmon). Broken lines
indicate energetically favorable (magenta) and unfavorable (black) interactions (distances are indicated in A˚). Superimposition of the CDK2-14 complex (gray) with
a CDK9 (PDB #3BLR; salmon; E) and a CDK7 crystal structure (PDB #1UA2; salmon; F). The rmsd for the alignment of the CDK9 and CDK7 with the CDK2-14
coordinates (all atoms/ATP-binding site) was 2.39 A˚/0.78 A˚ and 1.65 A˚/0.92 A˚, respectively. For data collection and refinement statistics of the X-ray crystal struc-
ture complexes of CDK2 with compounds 11 and 14 refer to Table S3; PDB #2XMY and 2XNB.
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of Transcriptional Inhibitors
In order to determine the basis for the selectivity and potency of
CDK7 and CDK9 inhibitors, we determined complex crystal
structures with CDK2 for compounds 11 and 14 (Figures 4A–
4D). Furthermore, we used published X-ray crystal structures
of CDK7 (Lolli et al., 2004) and CDK9 (Baumli et al., 2008).
The CDK7 and CDK9 selectivity of compound 14, which
contains a piperazine substituent at the aniline para position,
can be rationalised by the replacement of Lys89 in CDK2 with
smaller residues in CDK7 and CDK9 (Figures 4E and 4F). Our
CDK2-14 complex crystal structure reveals that the bulky
piperazine ring results in unfavorable contacts with the Lys89
side chain (Figure 4D). As a result, this side chain is forced to
change position from that observed in apo- and ATP-bound
CDK2 structures (Brown et al., 1999; Wu et al., 2003), which is
energetically unfavorable. On the other hand, modeling suggests
that the residues corresponding to Lys89 in CDK2, i.e. Val100 in
CDK7 or Gly112 in CDK9 can better accommodate the piperazine
ring of 14. The complex structure of compound 14 with CDK2
and homology modeling with other CDKs further indicate that
electrostatic charge differences at the ATP-binding site of
CDK1 and CDK2 with respect to CDKs 4, 7, and 9 play a signifi-
cant role in the selectivity of this compound. Because CDKs 4, 7,
and 9 all have a nonionizable side chain in the Lys89 position,
there is less repulsion with the positive charge on the piperazine
ring (McInnes et al., 2004).1116 Chemistry & Biology 17, 1111–1121, October 29, 2010 ª2010 EFor compound 11, which, unlike the piperazine ring of
compound 14, has a flexible sulfonamide substituent, the situa-
tion is different. Here the p-anilino sulfonamide can be observed
tomake strongH-bonding interactionswith the side-chain amino
group of Lys89 in CDK2 (Figure 4C). Similar interactions are not
possible with CDK7 and CDK9, where small lipophilic residues
are present in place of Lys89.
The selectivity of the methylsulfone compounds 6 and 7
derives from differences in the residues that correspond to
Gln131 in CDK2. This is Ala153 in CDK9, which is capable of
forming favorable van derWaals contactswith the sulfonemethyl
groups. The increasing CDK9 selectivity of compounds 4, 5, and
8–10, on the other hand, can be explained by the increase in
steric bulk of the extensions of the sulfonamides at the aniline
meta position. As we have shown, compounds with small aniline
meta substituents, e.g., the nitro derivative 1, adopt CDK2
binding poses with two distinct aniline orientations (Wang
et al., 2004a). Modeling shows that unfavorable intramolecular
interactions of the sulfonamide extensions in compounds 4, 5,
and 8–10 with the thiazole/thiazolone head groups force the
aniline rings to project toward the position occupied by Lys89 in
CDK2, resulting in unfavorable contacts. From the crystal struc-
tures of CDK7 and CDK9 it is apparent that the region around
Lys88-Lys89 (in the CDK2 context) is considerably more open in
CDK7, and especially in CDK9, due to the presence of the smaller
side chains of the corresponding residues (Glu99-Val100 and
Ala111-Gly112 in CDK7 and CDK9, respectively).lsevier Ltd All rights reserved
Figure 5. Status of Key Cellular Proteins
Following Treatment with Compound 14
After exposure of A2780 cells to 14 (A) CTD phos-
phorylation of Ser-2 and Ser-5 of RNAP-II is signif-
icantly reduced after 3 hr. p53 levels have
increased and levels of the antiapoptotic protein
Mcl-1 have been reduced, while XIAP remains
fairly constant at early time points. There is no
reduction in phosphorylation of pRb at the 249/
252, 780, or 821 sites. After 24 hr treatment with
14 (B) both the transformed A2780 and untrans-
formed WI-38 cell lines show a similar primary
response. There is a reduction in phosphorylation
of the CTD of RNAP-II at Ser-2 and Ser-5, an
increase in p53, and a decrease in each of the
antiapoptotic proteins XIAP, Mcl-1, and survivin.
Only A2780 cells show cleavage of PARP,
however, suggesting that apoptosis has been initi-
ated in these cells. See also Figure S3.
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In Vitro Antiproliferative Activity
On the basis of its in vitro kinase potency, selectivity, and phar-
maceutical properties, a detailed study of the cellular mode of
action of 14 was carried out. It was screened against a panel
of human leukemia and solid tumor cell lines (Table S1C).
A broad spectrum of in vitro antitumor activity was observed,
with an average IC50 value of 0.3 mM. There was no selectivity
toward cell line types based on p53, p21, p16, or pRb status.
Selectivity toward transformed versus untransformed cell lines
was observed: 14 was 20- and 40-fold less potent against fetal
lung fibroblast lines WI-38 and IMR-90, respectively, compared
with the tumor cell lines examined.
RNAP-II CTD Phosphorylation and p53 Induction
In accordance with the biochemical enzyme inhibition data
showing 14 to be a potent inhibitor of CDK7 and CDK9, the
phosphorylation of both Ser-2 and Ser-5 of the RNAP-II CTD
was reduced significantly after 3 hr in A2780, with WI-38 cells
showing a similar response at 24 hr (Figure 5). Protein levels of
p53 were induced at early time points since p53 is regulated at
the translational level, but p21 levels, normally upregulated by
p53-dependent transcription, did not rise due to inhibition of
transcription by 14.
Reduction of Antiapoptotic Protein Levels
At 3 hr, Mcl-1 levels were reduced in A2780 cells. After 24 hr,
A2780 andWI-38 cells both showed a reduction in antiapoptotic
proteins XIAP,Mcl-1, and survivin (Figure 5). A2780 cells showed
a greater reduction in levels of survivin and XIAP than WI-38
cells. Both cell lines showed reductions in Mcl-1. It is interesting
to note that A2780 cells possess much greater levels of Mcl-1
than WI-38 in untreated samples.
Selective Induction of Apoptosis in Transformed Cells
Apoptosis is induced in A2780 cells, as detected by caspase-3/7
assay, at concentrations of 0.31 mM 14 and above. WI-38 cells,
however, were completely insensitive even at 10 mM 14 (Fig-
ure 3A), despite showing sensitivity to mechanistically unrelated
kinase inhibitor compounds. This result confirms the selectivity
for transformed cells seen in the MTT proliferation assay (Table
S1C). TUNEL analysis, in conjunction with DNA staining, showed
that 50% of cells were TUNEL positive after 24 hr with 2 mM 14Chemistry & Biology 17, 1111–1(Figure 3B). These apoptotic cells were observed in all cell cycle
compartments, suggesting that this class of inhibitor causes cell
death at each stage of the cell cycle and does not lead to
a stage-specific cell cycle block. A reduction in the levels of anti-
apoptotic proteins occurred in both transformed (A2780) and
untransformed (WI-38) cell lines. However, PARP cleavage
(Figure5) only occurred in theA2780cell line, suggesting that anti-
apoptotic proteins may play a less important role in the untrans-
formed cells than in the oncogenically transformed cells.
Selective CDK9-Cyclin T Inhibition Also Induces
the Transcriptional-Type Response in Cells
Compounds 3, 10, and in particular, compound 9, showed
greater selectivity for CDK9 over CDK7. Figure 2 shows that at
the concentrations of compounds needed to induce cellular
cytotoxicity, the contribution of CDK7 inhibition is negligible.
From the screening cascade these compounds belonged to
class-1 and further analysis of key cellular proteins showed
a significant reduction in RNAP-II CTD Ser-2 phosphorylation,
a slightly weaker reduction in Ser-5 phosphorylation, an induc-
tion of p53, and a reduction in Mcl-1 levels after 3 hr exposure
in A2780 cells (Figure S3). These responses are consistent with
that shown by 14, an approximately equipotent CDK7 and
CDK9 inhibitor. Like 14, the CDK9-specific inhibitors 3, 9, and
10 induced apoptosis selectively in transformed cells (Table S2).
In Vivo Anti-Tumor Activity of Compound 14
Compound 14 was evaluated for in vivo antitumor activity using
a P388/0 murine leukemia survival model (Marsh et al., 1985).
When dosed twice daily for 10 days with 14, animals experi-
enced an increase in life span of 68%, 45%, and 36% at doses
of 30, 20, and 13 mg/kg/dose, respectively (p < 0.0001)
(Figure S2A). The treated animals suffered no weight loss
compared to animals receiving vehicle only and the maximum
tolerated dose (MTD) of 14 was not achieved in this experiment,
indicating a good therapeutic margin.
Compound 14alsodemonstrated antitumor activity in amurine
xenograft solid tumor model using the human colorectal
Colo-205 cell line. As a positive control 5-fluorouracil (5-FU),
the chemotherapy drug most commonly used in the clinic for
colorectal cancer, was included on an optimal intravenous121, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1117
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istered by either the intraperitoneal (i.p.) or oral route (Fig-
ure S2B). When given at 50 mg/kg i.p. every day for 8 days, 14
produced a specific tumor growth delay of 10.5 days
(p < 0.05). Similarly, 14was active and well tolerated when given
by the same schedule at 100 mg/kg p.o., resulting in a tumor
growth delay of 7 days (p < 0.05). On the last evaluable day the
tumor versus control ratios (T/C) were below 40% at the top
dose by both administration routes. By comparison, 5-FU was
considerably less active at its MTD of 50 mg/kg, given every
4 days for four treatments, and only yielded a tumor growth delay
of 1 day.
DISCUSSION
The work presented here explores the biomedical rationale for
the development of pharmacological inhibitors of transcription.
This effect is achieved with kinase inhibitors that target predom-
inantly CDK9-cyclin T1 and is further explored by studying the
effects of simultaneously inhibiting CDK7 and CDK2, additional
CDKs thought to be responsible for the regulation of RNAP-II
activity through phosphorylation of its CTD.
The current model of RNAP-II regulation postulates
a sequence in which CDK7 first phosphorylates CTD Ser-5
residues as part of transcription initiation (Sims et al., 2004).
Subsequent dephosphorylation of Ser-2, and then phosphoryla-
tion of Ser-2 residues by CDK9 (Zhou et al., 2000) is necessary
for the transition to RNA elongation (Price, 2000). Detailed
analysis of CTD phosphorylation by CDKs 7, 8, and 9 (Ramana-
than et al., 2001) have shown all three kinases to be capable of
phosphorylating Ser-5, but not Ser-2, of a CTD peptide in vitro,
despite evidence of in vivo phosphorylation at both Ser-2 and
Ser-5 residues. This seems to correlate with the concept of
stepwise phosphorylation, with Ser-5 phosphorylation being
the initiating event, while Ser-2 becomes phosphorylated only
after other criteria are met. Another study has highlighted the
nonuniformity of CTD phosphorylation, showing that each of
the three kinases produces different patterns of phosphorylation
of the CTD, but that only CDK7 efficiently produces hyperphos-
phorylated substrates (Pinhero et al., 2004). These studies
suggest that CTD phosphorylation is regulated in a complex
manner, with changes in substrate specificity depending upon
the transcriptional state of the complex and the accessibility of
different regions of the CTD.
Each of our transcriptional-type inhibitor compounds is
capable of reducing the phosphorylation of Ser-2 and Ser-5 of
the CTD of RNAP-II. There is a differential response in the phos-
phorylation state of Ser-2 and Ser-5, with quicker and more
pronounced dephosphorylation of Ser-2 over Ser-5. At this stage
we cannot conclusively demonstrate kinase specificity for each
site as this difference may be due to different phosphatase activ-
ities or site accessibility. However, compounds 3, 9, and 10, that
we postulate to possess no appreciable CDK7 activity at the
concentrations used to elicit a cytotoxic IC50 response (Figure 2),
can still cause a reduction in Ser-2 phosphorylation after 3 hr and
initiate events that lead to the subsequent induction of
apoptosis. These data lend support to the hypothesis of CDK9
targeting the Ser-2 site of RNAP-II and that inhibition of CDK9
is sufficient to inhibit transcription.1118 Chemistry & Biology 17, 1111–1121, October 29, 2010 ª2010 EThe transcriptional activity of RNAP-II is required in all cells
and inhibition of RNAP-II may thus not immediately present itself
as a rational target for cancer therapeutics. However, trans-
formed cells have a greater requirement for enhanced transcrip-
tional activity. First, their increased rate of proliferation necessi-
tates increased protein production. Second, cells are genetically
predisposed to enter into programmed cell death upon onco-
genic stimulation, but a few may be able to transform into an
apoptosis-resistant, rapidly proliferating state by a number of
means. One way of avoiding apoptotic death is the increased
production of antiapoptotic proteins in order to counteract the
presence of the proapoptotic proteins induced by the initial
transforming event (Koumenis and Giaccia, 1997). The cancer
cell achieves a new balance, but at the expense of continuously
increased production of these antiapoptotic proteins, many of
which have short half-lives at both the mRNA and protein levels.
The fully transformed cell is thus committed to a strategy of
increased protein production and therefore increased transcrip-
tion in order to maintain the status quo of cell survival over pro-
grammed cell death.
The increased production of antiapoptotic proteins in trans-
formed cells is well documented (Liston et al., 2003; Schimmer,
2004). For example, elevated levels of survivin, XIAP, cIAP1, and
cIAP2 have been shown in human prostate cancers and in pros-
tate tissues from transgenicmice expressingSV40 large T antigen
(Krajewska et al., 2003). Survivin is highly expressed in many
transformed cells but is rarely detected in normal adult tissues
(Zangemeister-Wittke and Simon, 2004). Mcl-1 is a member of
the anti-apoptotic Bcl-2 family (Cory et al., 2003) whose expres-
sion decreases when cells undergo apoptosis (Iglesias-Serret
et al., 2003). Increased Mcl-1 protein levels have been reported
in a number of tumor samples (Khoury et al., 2003; Song et al.,
2005), and a difference in expression may be observed in the
control lanes of A2780 and WI-38 (Figure 5).
Weshow that asa result of decreased transcription, the expres-
sion levels of a number of highly expressed, short half-life, antia-
poptotic proteins suchasMcl-1, survivin, andXIAPdecline rapidly
in both transformed and untransformed cell lines. We demon-
strate that although the primary events of dephosphorylation of
RNAP-II, induction of p53, and downregulation of antiapoptotic
proteins, is consistent across transformed and untransformed
lines, the ultimate fate of the cell is governed by its reliance
upon antiapoptotic proteins for continued survival. This results
in a selective apoptotic response, demonstrated by strong induc-
tion of caspase-3/7 activity, PARP cleavage, and appearance of
TUNEL-positive cells in transformed cell lines only.
The induction of p53, a protein whose expression is tightly
regulated at the posttranslational level by its association with
Mdm2, itself a short half-life protein that is affected by reduced
transcriptional activity, may contribute to the apoptotic
response. p53 may translocate to the mitochondria and induce
apoptosis through its direct interaction with, and activation of
proapoptotic proteins such as Bax (Arima et al., 2005). However,
as we see no differential sensitivity between p53 wild-type and
p53 mutant or null cells in our cytotoxicity assays and have
demonstrated that the response is not part of a DNA damage
response, we conclude that this effect is not integral to
compound mode of action and we simply utilize this induction
as part of our screening cascade. The increase in p53 levels islsevier Ltd All rights reserved
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regulated by p53 activity), a response in keeping with transcrip-
tional inhibition.
SIGNIFICANCE
The work described here highlights our current under-
standing of transcriptional-type CDK inhibitors and demon-
strates how this knowledge can be adapted to provide an
efficient screening cascade for the identification of such
compounds. We have profiled a number of compounds
with the ability to reduce the phosphorylation of Ser-2 and
Ser-5 of the CTD of RNAP-II through inhibition of CDK9-cy-
clin T and CDK7-cyclin H and selectively kill transformed
cells as a result of this inhibition. Our work shows that
although both transformed and untransformed cells show
a similar reduction in antiapoptotic proteins due to inhibition
of RNAP-II CTD phosphorylation, untransformed WI-38 lung
fibroblasts do not undergo apoptosis, thus demonstrating
a differential response to the downstream events that cause
transformed cells to undergo apoptosis through the cas-
pase pathway. In vivo experiments have also demonstrated
a good tolerance for compound 14 and significant increases
in life span and antitumor activity in mouse models. We thus
conclude that an untransformed cell, with intact check-
points, low oncogenic stress, and lower levels of apoptotic
proteins may have a significant tolerance toward transient
inhibition of RNAP-II activity, whereas the equivalent trans-
formed cell would be much more susceptible to this type
of inhibition and undergo a caspase-induced apoptotic
death.
EXPERIMENTAL PROCEDURES
Synthesis and Compound Characterization
Preparation of [4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-
phenyl)-amine (1) was described (Wang et al., 2004a). Compounds 2–14




MI was determined by an automated fluorescence microscopy 96-well plate
assay using the Cellomics Arrayscan Mitotic Index HitKit protocol (Cellomics
Inc.). In brief, cells were plated at 104 cells per well and incubated for 18 hr
at 37C. Test compounds were added and cells were incubated for the appro-
priate time before a 15 min fixation in 3.7% formaldehyde in PBS. Cells were
permeabilized in PBS with 0.2% Triton X-100 for 15 min, washed, and incu-
bated with a primary antibody that specifically recognizes a mitotic epitope
(rabbit anti-phosphoserine-10 histone-H3, Upstate 06-570). After incubation
with a secondary FITC-conjugated anti-rabbit antibody and Hoechst 33258
dye, cells were washed and analyzed using the Cellomics Arrayscan II auto-
mated fluorescent microscopy system to detect nuclear fluorescent staining.
Data for 2000 cells per well were collected and the Cellomics mitotic index
algorithm used to calculate mitotic index (MI; percentage of cell nuclei stained
with the mitosis-specific antibody versus total cell nuclei stained with Hoechst
33258 dye). A similar assay was carried out for DNA damage by substituting
a mouse antibody specific for the DNA damagemarker histone H2AX (Upstate
17-327A) as the primary antibody and FITC-conjugated anti-mouse antibody
as secondary antibody.
p53 Stabilization Assay
Cells were plated at 104 cells per well and incubated for 18 hr at 37C. Test
compounds were added and cells were incubated for the appropriate timeChemistry & Biology 17, 1111–1before a 3 min fixation in cold (20C) 50:50 v/v methanol/acetone. The fixed
cells were dried briefly then washed with PBST (PBS, 0.1% Triton X-100) and
incubated with primary CM-1 rabbit anti-human p53 antiserum (Midgley et al.,
1992) diluted 1:1,000. After incubation with a secondary Alexa Fluor 488 goat
anti-rabbit antibody (Molecular Probes, A11008) and Hoechst dye, the cells
were washed and analyzed using the Cellomics Arrayscan II automated fluo-
rescent microscopy system to detect nuclear fluorescent staining. Data for
2000 cells per well were collected and the Cellomics mitotic index algorithm
used to calculate percentage of cell nuclei stained with p53-specific antibody
versus total cell nuclei stained with Hoechst.
MTT Cytotoxicity Assays
Standard MTT (thiazolyl blue; 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zolium bromide) assays were performed after 72 hr treatment with test
compounds (Haselsberger et al., 1996).
Determination of Apoptosis
Apoptosis was determined by either a terminal deoxynucleotidyl transferase-
mediated nick end labeling (TUNEL) assay (ApoDirect BD), following
manufacturer’s instructions, or by caspase-3/7 assay (Caspase-Glo 3/7 assay,
Promega), following manufacturer’s instructions, with cells seeded at 10,000
per well of a 96-well plate in a total volume of 100 ml medium per well. Assays
were performed 24 hr after test compound addition. Detection reagent (100 ml)
was added directly to each 100 ml sample and readings were taken after
a further 30 min incubation at room temperature.
Western Blot Analysis
Total protein cell lysates (10 mg) were run on SDS-PAGE (4%–12% gradient)
gels (Novex) under reducing conditions. The separated proteins were trans-
ferred to membranes and were probed with antibodies specific for pRb (BD),
249/252 pRb (BioSource), RNAP-II, RNAP-II Ser-2, RNAP-II Ser-5 (Covance),
p53 (Oncogene ab-6), p21, PARP, Mcl-1 (Santa Cruz), XIAP, survivin (Novus),
and actin (Sigma).
In Vitro Kinase Assays
Details for the cloning, expression, and purification of His-tagged CDK9/cyclin
T1 are provided as Supplemental Experimental Procedures.
Kinase Assays
CDK and other kinase assays were carried out as previously described (Wang
et al., 2004a). IC50 values were calculated from ten-point dose-response
curves and apparent inhibition constants (Ki) were calculated from the IC50
values and appropriate Km (ATP) values for the kinases in question (Cheng
and Prusoff, 1973).
Pharmacology
Screening, biopharmaceutical profiling, PK determinations, and evaluation of
anti-tumor efficacy of test compounds are described in the Supplemental
Experimental Procedures.
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